PNC Managed Account Solutions’s Regeneron Pharmaceuticals REGN Stock Holding History

PNC Managed Account Solutions’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	$314K	Buy	+562	New	+$285K	0.06%	172

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Harris Associates Chicago, Illinois $75B AUM 11.27% 1-Year Est. Return

PNC Managed Account Solutions's REGN Position: Q2 2021 in Review

PNC Managed Account Solutions opened a new position in Regeneron Pharmaceuticals (REGN) in Q2 2021: 562 shares worth $314K. The stake represents 0.06% of the portfolio and ranks #172 among its holdings.

971 funds tracked by Wall St. Rank hold REGN as of Q2 2021.

PNC Managed Account Solutions held 562 shares of Regeneron Pharmaceuticals worth $314K as of Q2 2021.
Regeneron Pharmaceuticals was a new PNC Managed Account Solutions position in Q2 2021.
Regeneron Pharmaceuticals made up 0.06% of PNC Managed Account Solutions's portfolio in Q2 2021, its #172 holding.
971 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2021.

Based on PNC Managed Account Solutions's 13F filing for Q2 2021, filed 6 Aug 2021.